"Theyre already starting to narrow what can be prescribed," she told AAP. "Its very frustrating." Credit & Reference: AAP, October 26
“The compassionate access available to a very limited number of pediatric
epilepsy patients, 30 in this state, which has cost taxpayers $6 million, is only supplying a single-molecule product," she said. "(It) has had limited success compared with full plant extracts, which include the full spectrum of cannabinoids."”
Ms Carter and Dr Alex Wodak are due to speak on the issue at a forum in Brisbane on Thursday evening.